The NICE has issued final draft guidance endorsing the use of CSL Vifor's Filspari (sparsentan) for primary IgA nephropathy.

Aptar Digital Health has signed a licensing agreement with AstraZeneca for detecting CKD using the latter’s AI-driven ...

In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...

GSK has received approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab).

Genentech has announced an investment exceeding $700m to establish its first East Coast manufacturing facility in North ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Artificial Intelligence (AI) is now used throughout clinical trials, from recruitment to analysis – but are regulators ...

Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for ...

Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act. The EU Artificial Intelligence (AI ...

An ATS 2025 session presented data showing that anti–IL-5 biologics significantly cut exacerbations in coexisting asthma and ...

The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their ...